Bavarian Nordic's new smallpox vaccine factory ready mid-2005  

2004.04.01
The Danish biopharmaceutical company has announced that its new smallpox vaccine factory is expected to become operational mid-2005

Biopharmaceutical company Bavarian Nordic has announced that its new smallpox vaccine factory is expected to become operational mid-2005. Bavarian Nordic is reconstructing its Kvistgård facilities (north of Copenhagen) in cooperation with Novo Nordisk Engineering (NNE). The production plant will have a production capacity of up to 120 million vaccine doses per year. Bavarian Nordic has also announced that it has selected the name IMVAMUNE as the brand name for its MVA-BN small pox vaccine.

 

Bavarian Nordic was founded in 1994 and employs 100 people. The biopharmaceutical company leads the field in innovative vaccines to prevent infectious diseases. Concerning smallpox vaccines, Bavarian Nordic has development and supply contracts with a number of governments including Germany and the US. Partners include Epimmune, Gerolymatos, Impfstoffwerk Dessau-Tornau and Vaccine Solutions. The news is reported by financial newspaper Børsen online and on Bavarian Nordic's website.

 

Link > Bavarian Nordic 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×